Riferimenti Bibliografici:
Riferimenti bibliografici:
[1] Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the rheumatic diseases 2012 Nov;71(11):1771-82 (full text)
[2] Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis and rheumatism 2002 Apr;46(4):995-1002
[3] Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clinical journal of the American Society of Nephrology : CJASN 2008 Jan;3(1):46-53 (full text)
[4] Faurschou M, Starklint H, Halberg P et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. The Journal of rheumatology 2006 Aug;33(8):1563-9
[5] Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the rheumatic diseases 2010 Jan;69(1):61-4
[6] Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis and rheumatism 2004 Aug;50(8):2559-68 (full text)
[7] Moroni G, Quaglini S, Gallelli B et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007 Sep;22(9):2531-9 (full text)
[8] Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis and rheumatism 2012 Apr;64(4):1215-26 (full text)
[9] Moroni G, Gallelli B, Sinico RA et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Annals of the rheumatic diseases 2012 Oct;71(10):1751-2
Per inserire una domanda, segnalare la tua esperienza, un tuo commento o una richiesta di precisazione fai il login con il tuo nome utente e password.
Se non lo sei ancora puoi registrati partendo da qui.